BRAINSTORM CELL THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended | ||||||
| · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| · · U.S. $ in thousands | ||||||
| Operating expenses: | | | ||||
| | | | | | | |
| Research and development, net (Note 12) | | $10,746 | | $13,956 | ||
| General and administrative | | 10,693 | | 10,866 | ||
| | | | | | | |
| Operating loss | | (21,439) | | (24,822) | ||
| | | | | | | |
| Financial income (expense), net | | (447) | | 545 | ||
| | | | | | | |
| Gain on change in fair value of Warrants liability (Note 9) | | | 4,694 | | | — |
| | | | | | | |
| Net loss | | $(17,192) | | $(24,277) | ||
| | | | | | | |
| Basic and diluted net loss per share | | $(0.40) | | $(0.66) | ||
| | | | | | | |
| Weighted average number of shares outstanding used in computing basic and diluted net loss per share | | 43,075,938 | | 36,509,060 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.